Companies involved in stem cell therapies, cannabis overdose treatments, COVID-19 vaccinations and the treatment of lupus make up the four new biotech stocks to watch highlighted in today’s article, which also highlights a number of new stocks to watch in the mining sector (including those involved in “battery metals” such as graphite and lithium). For all of these new stocks…
Strong and sustained share price appreciation, solid upside potential, an outlook toward further growth, and approval from Wall Street analysts characterize the three “monster growth stocks” highlighted in today’s article – all of which are hovering at or near one-year highs and have the potential to reach new highs. For these three stocks – including a developmental-stage biopharmaceutical company focused…
Although a controversial decision, the FDA has approved Biogen’s Alzheimer’s drug, Aduhelm – and the decision caused Biogen’s stock to surge more than 60% in one day. On the heels of this, and with novel drug approvals on the rise, the contributors to today’s article discuss Biogen’s approval “and how ‘novel’ drugs can give biotech stocks a leg up ……
A push to ramp up production of successful COVID-19 vaccines, continued demand for effective COVID-19 treatments, and an increased focus on other critical, non-COVID diseases are driving growth in the biotech industry – and against this backdrop, the author of today’s article highlights four particular biotech stocks that should see significant growth in the coming months. For these four stocks,…
While the author of today’s article acknowledges that, “Of course, it can be challenging for investors to navigate around the complexities that come with the biotech industry,” he advises that, “with proper research and due diligence, investors could make educated guesses on which biotech stocks to bet on.” So which biotech stocks are worth watching heading into June? For the…
“A big, headline-grabbing company is not always your best bet, assuming you’re a shrewd investor seeking to maximize your profits,” advises the author of today’s article – and this may be especially true when it comes to biotech stocks. What two “size benefits” do smaller companies have – and why does the “size factor” work? CLICK HERE.
The pharmaceutical company featured in today’s article, known for its innovative drug pipeline, is a late-stage biotech focused on developing novel, oral, small-molecule drugs for rare and serious diseases. Having gained 153.8% over the past year and 60.1% year-to-date, is this a good biotech stock to own? For a look at the factors that could influence its performance in the near…
When it comes to what makes a good tech company – and the secret to investing in the right one – the author of today’s article declares the following: “There’s one rule that I follow when investing in tech, and it’s served me well over my entire career…” What is this rule – and the secret to investing in tech?…
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s article of the five stocks he highlights, all of which are smaller-cap tech companies trading under the $10 level. For these five tech stocks, CLICK HERE.
“The best big pharma stocks offer growth potential thanks to strong pipelines, steady income with dependable dividends, and the opportunity to invest in a business that can make a huge positive impact in the lives of millions of people,” advises the author of today’s article, who proceeds to highlight three such pharma stocks that may be among the best picks…